SUMMIT THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.555 USD | +1.00% |
|
-2.37% | +73.95% |
| May. 07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
| May. 01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Presenter SpeechRichard Pye (Executives)Thank you, and welcome to everyone joining us on the c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.559
GBP
Average target price
5.994
GBP
Spread / Average Target
+68.39%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +73.95% | 3.17B | |
| +8.64% | 114B | |
| +10.33% | 104B | |
| -12.69% | 22.41B | |
| -0.41% | 22.28B | |
| -5.80% | 19.07B | |
| -37.36% | 18B | |
| -5.36% | 17.89B | |
| +6.83% | 14.28B | |
| +36.31% | 12.55B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Transcript : Summit Therapeutics plc, Q2 2020 Earnings Call, Oct 11, 2019